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SIROLIMUS ENHANCES THE EFFECT OF APOPTOTIC CELL INFUSION ON 
HEMATOPOIETIC ENGRAFTMENT AND TOLERANCE INDUCTION 
Letter to the Editor 
Allogeneic hematopoietic cell transplantation (AHCT) is an efficient and widely used treatment 
for various hematological diseases. However, the potential benefit of AHCT may be offset by 
graft-versus-host disease (GVHD) as well as other transplant-related toxicities. The development 
of the so-called non-myeloablative or reduced intensity conditioning regimens (RICR) has 
widened the indications of AHCT to a broader spectrum of elderly patients usually not candidate 
for standard myeloablative AHCT and diseases other than acute leukemia.1 However, and 
despite some initial enthusiasm,1 GVHD remains a matter of concern after RICR AHCT. 
Moreover, highly immunosuppressive regimens associated with the use of RICR may 
significantly increase the rate of infectious complications and delay immune reconstitution.2, 3 
Alternative approaches to favor engraftment and limit long-term post-transplant 
immunosuppression are still needed. 
Intravenous (i.v.) apoptotic cell infusion can modulate alloreactivity by interacting with particular 
dendritic cell subsets.4 We have previously established that i.v. apoptotic cell infusion facilitates 
engraftment –when administrated with allogeneic bone marrow (BM) transplants– without 
triggering autoimmunity or GVHD.5 This effect relies on a TGF--dependent mechanism.5 
Furthermore, i.v. apoptotic cell infusion is associated with a CD4+CD25+ regulatory T cell (Treg) 
increase early after BM transplantation (BMT) (day 6 and 8).5 These Tregs expressed high 
levels of Foxp3 transcripts and exerted a potent ex vivo suppressive activity through a cell-to-cell 
contact mechanism.5 Nonetheless, such results5 were achieved without administration of 
immunosuppressive drugs. In human settings, immunosuppressive treatments are mandatory, at 
least during the early phase of AHCT, until tolerance is fully established. Since 
immunosuppressive drugs are capable of interfering with long-term tolerance induction,6 we 
investigated whether the widely used immunosuppressive drugs (cyclosporin A [CsA], 
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mycophenolate mofetil [MMF], or sirolimus [SRL]) can modulate the effect of apoptotic cells co-
administrated with a hematopoietic graft in a murine BMT model. 
BMT was performed, as described,5 according to institutional guidelines and our local ethic 
committee. Six gray (Gy) sub-lethally irradiated BALB/c (H-2d, Thy-1.2) recipient mice (Janvier, 
Le Genest Saint Isle, France) were grafted with allogeneic FvB (H-2q, Thy-1.1) BM (106 cells), 
with or without FvB apoptotic splenocytes (5.106 cells; apoptosis was induced by a 40 Gy γ-
irradiation),5 and received immunosuppressive treatment for the next 14 days. 
Immunosuppressive drugs were administered intra-peritoneally as follows: CsA (Novartis 
Pharma, Rueil-Malmaison, France) 50 mg/kg/d from day 0 to 14,7 diluted in sterile saline 
solution; SRL (Wyeth Research, Monmouth Junction, NJ) 1.5 mg/kg/d from day 0 to 14, diluted 
in sterilized medium consisting of 160 mg of carboxy-methyl-cellulose (Sigma Aldrich, Saint 
Louis, MO) in 80 ml of sterile water,7 MMF (Roche, Mannheim, Germany) 20 mg/kg/d from day 0 
to 14, diluted in sterile saline solution.6 These immunosuppressive regimens were selected as 
the standard ones used for in vivo immunosuppression in other mouse models.6, 7 Engraftment 
was evaluated on peripheral blood cells by flow cytometry analysis (CyAnLX cytometer, 
DakoCytomation, Fort Collins, CO) at day 30 post-BMT using H-2- or Thy1-specific antibodies 
(BD Biosciences PharMingen, Le Pont de Clay, France).5 Engraftment was considered to be 
achieved if at least 15% of recipient peripheral leukocytes had the BM donor H-2q or Thy1.1 
phenotype.5 After confirming the enhancing effect of apoptotic cell infusion on engraftment (40% 
of engrafted mice vs. 5% without apoptotic cell infusion, p=0.02), we investigated the 
interactions with the immunosuppressive drugs (Table 1). CsA treatment did not increase BM 
engraftment in mice receiving BM alone (14% of engrafted mice in the CsA group vs. 5% in the 
control group, p=0.76). However, in mice receiving both BM and apoptotic cells, CsA 
antagonized the favorable effect of apoptotic cells (6% of engrafted mice in the CsA group vs. 
40% without CsA; p=0.04). Similarly to CsA, MMF did not significantly promote engraftment in 
mice receiving BM alone (7% of engrafted mice vs. 5% without MMF, p=0.52). However, and in 
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contrast to CsA, engraftment after BM and apoptotic cells infusion was comparable between 
recipients treated with MMF or not treated (40% vs. 40% of engrafted mice, p=0.78). On the 
other hand, SRL dramatically increased hematopoietic engraftment in the group of mice grafted 
with BM alone (93% engrafted mice vs. 5% without treatment, p<0.0001), as well as in the group 
grafted with BM and apoptotic cells (100% of engrafted mice vs. 40 % without treatment; 
p<0.0001). Engraftment was not significantly different between the group of mice grafted with 
BM alone (93% of engrafted mice) and those grafted with both BM and apoptotic cells (100% of 
engrafted mice, p=0.78) in the presence of SRL (Table 1). 
In order to decipher a possible synergistic effect of SRL on apoptotic cell-induced engraftment, 
further experiments were performed with a lower number of BM cells (5.105 cells/mouse). 
Despite this low amount of BM cells, SRL treatment still allowed engraftment in 80% of recipient 
mice after infusion of BM alone (0% of engraftment in the absence of SRL, p<0.0001), and in 
100% of recipients receiving BM plus apoptotic cells infusion (as compared to 25% without SRL, 
p<0.0001)(Table 1). Most importantly, the combination of such a low number of BM cells, SRL 
treatment, and apoptotic cell infusion resulted in a 93+2% of circulating donor-derived cells in 
the peripheral blood 30 days post-transplantation (as compared to 57+11% with BM alone and 
SRL treatment, p<0.0001, Table 1). To further appreciate the effect of SRL on apoptotic cell-
induced engraftment, pre-transplant irradiation was reduced from 6 to 5 Gy. Similar results were 
obtained: after a 5 Gy conditioning regimen, SRL treatment allowed engraftment in 6 recipient 
mice out of 10 after infusion of BM cells alone whereas addition of apoptotic cells to the graft 
induced engraftment in all the mice. Thus, SRL exerts an additional beneficial effect on apoptotic 
cell-induced engraftment. 
To appreciate the impact of immunosuppressive drugs on apoptotic cell-induced engraftment, 
we analyzed splenic T-cell subsets in recipient mice at day 15 (i.e., the end of 
immunosuppressive treatment). No significant difference was observed in CD4/CD8 ratio 
whatever the analyzed group (Table 1). Treatment with CsA –but not with other drugs–
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significantly decreased the absolute numbers of CD4 and CD8 T cells in the spleen of mice 
receiving BM and apoptotic cells (Table 1). Since i.v. infusion of apoptotic cells in addition to a 
BM graft can induce a Treg increase in the spleen,5 we therefore asked whether Treg expansion 
after apoptotic cell infusion may be influenced by exposure to immunosuppressive drugs. 
Splenic Tregs (defined as CD4+CD25+Foxp3+ T cells) were evaluated by cytometry using anti-
Foxp3 mAb (FJK-16s eBioscience, San Diego, CA) at day 15 post-BMT. CsA treatment resulted 
in a significant decrease of splenic Tregs after apoptotic and BM cell infusion (2.4%+0.3 % vs. 
5.3+0.6% of CD4+CD25+Foxp3+ T cells without CsA, p<0.001). MMF did not significantly modify 
apoptotic cell-induced splenic Tregs (6.7+0.7% of CD4+CD25+Foxp3+ T cells). In contrast, SRL 
treatment combined with apoptotic cell administration, significantly increased splenic Tregs 
(7.5+0.6 vs. 5.3+0.6%, [p=0.013] of CD4+CD25+Foxp3+ T cells) (Figure 1 A-B). 
The above results prompted us to analyze long-term engraftment and tolerance to donor BM 
allo-antigens. This was assessed by a skin graft model. Full-thickness skin grafts (approximately 
1 cm², from the tail) obtained from FvB (BM donor) and C57BL/6 (third-party, H-2b) donor mice 
were grafted on the lateral thorax of BM (with or without apoptotic cells) recipient BALB/c mice 
and secured with a bandage for 10 days. Grafts were then monitored daily for the first 2 weeks, 
then twice a week. Rejection was defined as the complete loss of viable donor graft tissue. Skin 
graft tolerance was found to be closely linked to BM engraftment (Figure 2). Recipient mice 
treated with CsA and receiving BM cells alone or with apoptotic cells quickly rejected BM donor 
origin skin graft in the same way as naive mice. In contrast, BM engrafted mice that received BM 
and apoptotic cells and MMF (n=5) or SRL (n=10) or without immunosuppressive regimen 
(n=15), tolerated skin grafts from BM donor origin for up to 400 days (Figure 2). These mice kept 
the ability to reject a C57BL/6 third party skin graft (Figure 2), suggesting a long-term tolerance 
to BM donor Allo-Ag, when MMF or SRL were used as a transient immunosuppressive regimen 
together with apoptotic cell infusion. 
 5 
The use of donor apoptotic cell infusion can be proposed as an "alternative" cell-based approach 
to favor hematopoietic engraftment after RICR, modulate alloreactivity and limit excessive post-
transplant immunosuppression. Here, we studied the effect of the most commonly used 
immunosuppressive drugs on i.v. apoptotic cell infusion-induced engraftment. Our results 
establish that immunosuppressive drugs such as the calcineurin inhibitor CsA, commonly used 
in clinical transplantation, can interfere with apoptotic cell infusion-induced engraftment and 
long-term tolerance. In contrast, other drugs, such as SRL, can exert a positive effect, adding to 
the growing evidence on the differential impact of immunosuppressive drugs on tolerance 
induction.6, 7 
Induction of T cell tolerance requires TCR triggering.8 We have previously shown that, i.v. 
apoptotic cell infusion induces a TGF-β-dependent increase of Tregs.5 Addition of CsA after 
apoptotic and BM cell infusion resulted in a significant decrease of splenic Tregs, suggesting 
that CsA may prevent TGF-β-dependent conversion of Tregs induced by apoptotic cells. 
Moreover, CsA-dependent inhibition of IL-2 production may also interfere with apoptotic cell-
induced Treg expansion, since IL-2 is critical for the development and maintenance of Tregs in 
vivo.7 In contrast to CsA, SRL –targeting the mammalian Target of Rapamycin (mTOR) and 
acting downstream the IL-2 receptor– enhances Treg expansion,7 thereby amplifying the 
tolerogenic environment generated by apoptotic cell infusion at the time of BMT. Our current 
findings highlight a novel role for SRL in the apoptotic cell infusion-induced modulation of 
alloreactivity. 
From the practical standpoint, our findings constitute a step forward towards the use of i.v. donor 
apoptotic cell infusions to enhance engraftment in various clinical settings. Although CsA may 
exert a beneficial effect on GvHD, it is likely that CsA should be avoided with apoptotic cell 
infusion, as it may abrogate its favorable effect. Alternatively, MMF, which is commonly 
administrated in clinical practice for calcineurin inhibitor-intolerant hematopoietic cell recipients,9 
can be employed without interference with the action of apoptotic cells. Most interestingly, and 
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despite some adverse effects,10 SRL-based immunosuppressive regimens that are increasingly 
used in the solid transplant field can probably represent an attractive setting for the design and 
testing of tolerance induction in conjunction with donor apoptotic cell infusion. Moreover, i.v. 
infusion of apoptotic cells may mimic extracorporeal photochemotherapy (ECP), a therapeutic 
approach used to treat severe chronic or acute GvHD. Indeed, significant numbers of apoptotic 
leukocytes are generated post-ECP prior their re-infusion.11 In addition, Treg have been shown 
to be induced after ECP in a murine model.12 Whether CsA may interfere with ECP-induced Treg 
is an interesting question to address. Finally, based on the data reported here, SRL-based 
immunosuppressive regimens can be proposed as an interesting way to favor hematopoietic 
engraftment after RICR. 
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TABLE 1. Effect of immunosuppressive drugs on hematopoietic engraftment and on spleen T cell subsets after 
simultaneous infusion of BM and apoptotic cells 
 
BMT (6 Gy γ-
irradiation) 
IST % of engrafted 
mice (n)* 
p value
#
 % donor derived cells in 
engrafted mice
§ 
(mean±SEM [range]) 
CD4/CD8 CD4 T cells 
(x 10
6
) 
CD8 T cells 
(x 10
6
) 
CD4 T cell subsets
£
 (%): 
naive memory activated  
BM 5.10
5
 
BM 5.10
5
+Apo 
none 
none 
0% (0/20) 
25% (5/20) 
 0 
67+14 [27–98] 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
BM 10
6
 
BM 10
6
+Apo 
none 
none 
5% (1/20) 
40% (10/25) 
 79 
85+6 [15–100] 
1.0+0.3 
2.4+0.9 
6.8+1 
11.0+1.3 
6.8+0.4 
6.1+1.3 
ND 
25+5 
ND 
21+4 
ND 
50+5 
BM 10
6
 
BM 10
6
+Apo 
CsA 
CsA 
14% (2/14) 
6% (1/16) 
0.76 
0.04 
71.5+26.5 [45–98] 
100 
3.6+1.4 
4.6+2.3 
7.4+0.4 
6.2+1.3
‡
 
2.3+0.3 
1.9+0.5
‡
 
ND 
21+5 
ND 
15+3 
ND 
62+9 
BM 10
6
 
BM 10
6
+Apo 
MMF 
MMF 
7% (1/14) 
40% (6/15) 
0.52 
0.78 
54 
87+7 [60–100] 
1.5+0.6 
1.6+0.9 
10.1+1.3 
7.6+1.2 
6.9+0.5 
5.6+1.2 
ND 
27+7 
ND 
26+8 
ND 
45+13 
BM 10
6
 
BM 10
6
+Apo 
SRL 
SRL 
93% (13/14) 
100% (25/25) 
<0.0001 
<0.0001 
84+4 [55–98] 
80+3 [46–98] 
2.9+1 
2.7+1 
9.3+0.7 
10.9+1.3 
3.9+0.7 
4.4+0.5 
ND 
33+8 
ND 
21+2 
ND 
42+8 
BM 5.10
5
 
BM 5.10
5
+Apo 
SRL 
SRL 
80% (8/10) 
100% (10/10) 
<0.0001 
<0.0001 
57+11 [19–82]
†
 
93+2 [86–98]
†
 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
 
Abbreviations used: Apo, donor apoptotic splenocytes; IST, Immunosuppressive treatment; ND, not determined. *Engraftment was determined by flow cytometry 
analysis in peripheral blood 30 days after BMT as described in the text. 
#
p values obtained when compared with the same group without IST. 
§
% of donor-derived 
cells detected by cytometry. 
†
p<0.001. T cell subsets in the spleen (mean+SEM) were analyzed in 8-9 mice/group. 
‡
p<0.05 when compared with no IST. 
£
naive 
(CD44
low
/CD62L
high
), activated (CD44
high
/CD62L
high
), memory (CD44
high
/CD62L
low
) CD4 T cells were determined at day 15 using CD62L (Mel-14) and CD44 (IM7, 
BD Biosciences PharMingen) expression. Student’s t-test was used for group comparison. Pooled results from 2 to 4 independent experiments. 
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FIGURE LEGEND 
Figure 1. Effects of i.v. donor apoptotic cell infusion and immunosuppressive drugs on 
Foxp3+ Tregs.  
BALB/c mice were sub-lethally irradiated (6 Gy) and grafted with 106 FvB BM cells with or 
without 5x106 FvB apoptotic cells. CD4+CD25+Foxp3+ T cells were determined by flow cytometry 
in the spleen of recipient mice at day 15 (the day after the last infusion of immunosuppressive 
drug). (A) CsA inhibits i.v. apoptotic cell infusion-induced Tregs. Recipients grafted with BM cells 
plus apoptotic cells were treated for 14 days with the following immunosuppressive drugs: CsA 
(■, n=12), MMF (∆, n=9), SRL (●, n=9). Mice that received BM plus apoptotic cells were used as 
controls (▲, n=12). Pooled results of 2 to 4 independent experiments are expressed as mean + 
SEM of the percentage of CD4+CD25+Foxp3+ cells among CD3+ T cells. Bars correspond to the 
mean value of each group. (B) Representative dot plots showing CD25 and Foxp3 expression in 
the spleen of BALB/C mice on day 15 after BMT, having received BM cells plus apoptotic cells 
(BM + Apo) in conjunction with CsA, MMF or SRL. Note that CD3+CD4+CD25+Foxp3- cells are 
only detected in mice that did not receive immunosuppressive drugs. Student’s t-test was used 
for group comparison. 
 
Figure 2. Effects of i.v. donor apoptotic cell infusion and immunosuppressive drugs on 
long-term tolerance to donor bone marrow allo-antigens.  
Sub-lethally irradiated BALB/c recipient mice received an FVB BM allograft, with donor apoptotic 
leukocytes. Engrafted (■□) and non-engrafted (▲∆) BALB/c mice given donor FVB apoptotic 
and BM cells with or without immunosuppressive drugs were grafted with a donor (FVB, ▲■) 
and a third party (C57BL/6, □∆) skin graft 30 day post-BMT. Rejection was defined as the 
complete necrosis of graft tissue. (A) Engrafted BALB/c recipients after donor BM and apoptotic 
cell infusion tolerated a skin graft provided by BM donors (■), while retaining the capacity to 
reject a third-party skin graft (□). In contrast, non engrafted BALB/c mice rejected both donor (▲) 
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and third party (∆) skin graft. n = 15 mice/group from 3 independent experiments. (B) CsA 
prevents long-term tolerance to donor BM skin graft. The two mice (■□) considered to be 
engrafted at day 30 post-BMT rejected their skin grafts in the same way as non engrafted 
BALB/c mice (n= 5; ▲∆). Hematopoietic engraftment after CsA treatment was transient and lost 
at the time of skin graft, since donor-derived cells were not detectable at time of donor skin graft 
rejection in the 2 mice considered to be engrafted. In contrast, MMF (C) (n = 5 mice/group) or 
SRL (D) (n= 10 mice/group) treatment does not alter long-term tolerance to donor BM skin graft. 
Survival data were analyzed using Kaplan-Meier survival analysis. 
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Figure 1 
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Figure 2 
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